6-chloro-2-iodo-9-(2,3-di-O-acetyl-5-S-ethyl-5-thio-β-D-rubofuranosyl)-purine | 398139-00-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-chloro-2-iodo-9-(2,3-di-O-acetyl-5-S-ethyl-5-thio-β-D-rubofuranosyl)-purine
• 英文别名: [(2S,3S,4R,5R)-4-acetyloxy-5-(6-chloro-2-iodopurin-9-yl)-2-(ethylsulfanylmethyl)oxolan-3-yl] acetate
• CAS: 398139-00-9
• 化学式: C₁₆H₁₈ClIN₄O₅S
• 分子量: 540.766
• InChiKey: BQDKCRQISBZZEK-SDBHATRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-chloro-2-iodo-9-(2,3-di-O-acetyl-5-S-ethyl-5-thio-β-D-rubofuranosyl)-purine 在 氨 、 一水合肼 作用下， 以 甲醇 、 乙醇 、 异丙醇 为溶剂， 反应 82.0h， 生成 5'-S-ethyl-2-(N'-3-methyl-1-butylidenehydrazino)-5'-thioadenosine
  参考文献：
  名称：

  2,5‘-Disubstituted Adenosine Derivatives:  Evaluation of Selectivity and Efficacy for the Adenosine A₁, A_2A, and A₃ Receptor

  摘要：

  Novel 2,5'-disubstituted adenosine derivatives were synthesized in good overall yields starting from commercially available guanosine. Binding affinities were determined for rat adenosine A(1) and A(2A) receptors and human A(3) receptors. E-max values were determined for the stimulation or inhibition of cAMP production in CHO cells expressing human adenosine A(2A) (EC50 values as well) or A(3) receptors, respectively. The compounds displayed affinities in the nanomolar range for both the adenosine A(2A) and A(3) receptor, without substantial preference for either receptor. The derivatives with a 2-(1-hexynyl) group had the highest affinities for both receptors; compound 4 (2-(1-hexynyl)adenosine) had the highest affinity for the adenosine A(2A) receptor with a K-i value of 6 nM (A(3)/A(2A) selectivity ratio of approximately 3), whereas compound 37 (2-(1-hexynyl)-5'-S-methyl-5'-thioadenosine) had the highest affinity for the adenosine A(3) receptor with a K-i value of 15 nM (A(2A)/A(3) selectivity ratio of 4). In general, compounds with a relatively small 5'-S-alkyl-5'-thio substituent (methyl-5'-thio) displayed the highest affinities for both the adenosine A(2A) and A(3) receptor; the larger ones (n- or i-propyl-5'-thio) increased the selectivity for the adenosine A(3) receptor. The novel compounds were also evaluated in cAMP assays for their (partial) agonistic behavior. Overall, the disubstituted derivatives behaved as partial agonists for both the adenosine A(2A) and A(3) receptor. The compounds showed somewhat higher intrinsic activities on the adenosine A(2A) receptor than on the A(3) receptor. Compounds 37, 40 and 45, 48, with either a 5'-S-methyl-5'-thio or a 5'-S-i-propyl-5'-thio substituent had the lowest intrinsic activities on the adenosine A(2A) receptor. For the A(3) receptor, compounds 34, 35, 38, 39, and 46, 47, with a 5'-S-ethyl-5'-thio or a 5'-S-n-propyl-5'-thio substituent had the lowest intrinsic activities.

  DOI：

  10.1021/jm010952v
• 作为产物：
  描述：

  鸟苷 在 copper(l) iodide 六甲基磷酰三胺 、 4-二甲氨基吡啶 、 sodium hydroxide 、 氯化亚砜 、 二碘甲烷 、 四乙基氯化铵 、 碘 、 N,N-二甲基苯胺 、 三乙胺 、 三氯氧磷 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 2.25h， 生成 6-chloro-2-iodo-9-(2,3-di-O-acetyl-5-S-ethyl-5-thio-β-D-rubofuranosyl)-purine
  参考文献：
  名称：

  2,5‘-Disubstituted Adenosine Derivatives:  Evaluation of Selectivity and Efficacy for the Adenosine A₁, A_2A, and A₃ Receptor

  摘要：

  Novel 2,5'-disubstituted adenosine derivatives were synthesized in good overall yields starting from commercially available guanosine. Binding affinities were determined for rat adenosine A(1) and A(2A) receptors and human A(3) receptors. E-max values were determined for the stimulation or inhibition of cAMP production in CHO cells expressing human adenosine A(2A) (EC50 values as well) or A(3) receptors, respectively. The compounds displayed affinities in the nanomolar range for both the adenosine A(2A) and A(3) receptor, without substantial preference for either receptor. The derivatives with a 2-(1-hexynyl) group had the highest affinities for both receptors; compound 4 (2-(1-hexynyl)adenosine) had the highest affinity for the adenosine A(2A) receptor with a K-i value of 6 nM (A(3)/A(2A) selectivity ratio of approximately 3), whereas compound 37 (2-(1-hexynyl)-5'-S-methyl-5'-thioadenosine) had the highest affinity for the adenosine A(3) receptor with a K-i value of 15 nM (A(2A)/A(3) selectivity ratio of 4). In general, compounds with a relatively small 5'-S-alkyl-5'-thio substituent (methyl-5'-thio) displayed the highest affinities for both the adenosine A(2A) and A(3) receptor; the larger ones (n- or i-propyl-5'-thio) increased the selectivity for the adenosine A(3) receptor. The novel compounds were also evaluated in cAMP assays for their (partial) agonistic behavior. Overall, the disubstituted derivatives behaved as partial agonists for both the adenosine A(2A) and A(3) receptor. The compounds showed somewhat higher intrinsic activities on the adenosine A(2A) receptor than on the A(3) receptor. Compounds 37, 40 and 45, 48, with either a 5'-S-methyl-5'-thio or a 5'-S-i-propyl-5'-thio substituent had the lowest intrinsic activities on the adenosine A(2A) receptor. For the A(3) receptor, compounds 34, 35, 38, 39, and 46, 47, with a 5'-S-ethyl-5'-thio or a 5'-S-n-propyl-5'-thio substituent had the lowest intrinsic activities.

  DOI：

  10.1021/jm010952v

文献信息

• C2,5'-disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and pharmaceutical compositions containing them
  申请人：UNIVERSITEIT LEIDEN

  公开号：US20040127452A1

  公开（公告）日：2004-07-01

  The present invention concerns novel C2,5′-disubstituted and N6,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

  本发明涉及新型C2,5'-二取代和N6,C2,5'-三取代腺苷衍生物及其不同用途。这些腺苷衍生物被发现是有效的腺苷受体激动剂，因此在治疗和预防受腺苷受体激动剂影响的疾病和障碍方面具有治疗价值。
• C2,5'- disubstituted and N6, c2,5'- trisubstituted adenosine derivatives and their different uses
  申请人：——

  公开号：US20040132686A1

  公开（公告）日：2004-07-08

  The present invention concerns novel C2,5′-disubstituted and N 6 ′,C2,5′-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.

  本发明涉及新型的C2,5'-二取代和N6',C2,5'-三取代腺苷衍生物及其不同的用途。发现这些腺苷衍生物是有效的腺苷受体激动剂，因此在治疗和预防受腺苷受体激动剂影响的疾病和障碍方面具有治疗价值。
• US7084127B2
  申请人：——

  公开号：US7084127B2

  公开（公告）日：2006-08-01
• US7189706B2
  申请人：——

  公开号：US7189706B2

  公开（公告）日：2007-03-13